Summary
Since November 1981, 90 cancer patients treated with cytotoxic chemotherapy (CMF, FAC, FAM) have been studied to evaluate whether the administration of Synchrodyn® 1–17, 100 μg i.m. a day for 15 consecutive days, could reduce some side effects caused by the cytotoxic drugs. Nausea, vomiting and weakness which are the most frequent side effects generally found to be very upsetting to patients, were less pronounced in the treated patients than in patients treated with aplacebo. The performance status was not modified by the treatment. Skin pigmentation was noted in the majority of cases and it appeared to be related to the sustained treatment with high dosages of the peptide. Some side effects were observed in the treated patients such as sodium retention and hypertension, hyperglycemia. Successively we have begun to study the circadian rhythm of the cortisol, which often changes during the advanced stages of the illness and which chemotherapy does not seem to alter.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baker J. J., Lokey J. L., Price N. A., Bowen J., Winokur S. H.: Comparison of dexamethasone plus prochlorperazine toplacebo plus prochlorperazine as antiemetics for cancer chemotherapy— Proc. AACR/ASCO81, 35, 1980.
Calvert A. H.: Long-term sequelae of cytotoxic therapy—Cancer Topics3, 7, 1981.
Cooper A. F., McArdle C. S., Russel A. R., Smith D. C.: Psychiatric morbidity associated with adjuvant chemotherapy following mastectomy for breast cancer—Brit. J. Surg.66, 362, 1979.
Dorr R. T., Alberts D. S., Chen H. S. G.: The limited role of corticosteroids in ameliorating experimental doxorubicin toxicity in the mouse—Cancer Chemother. Pharmacol.5, 17, 1980.
Maguire G. P.: Psychosocial aspects and rehabilitation—Clin. Oncol.3, 833, 1982.
Maguire G. P., Tait A., Brooke M., Thomas C., Howat J. M. T., Sellwood R. A.: Psychiatric morbidity and physical toxicity associated with adjuvant chemotherapy after mastectomy— Brit. med. J.281, 1179, 1980.
Sallan S. E., Cronin C., Zelen M.: Antiemetics in patients receiving chemotherapy for cancer, a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine—New Engl. J. Med.302, 135, 1980.
Silberfarb P. M., Maurer H. L., Crouthamel C. S.: Psychosocial aspects of neoplastic disease. I. Functional status of breast cancer patients during different treatment regimens—Amer. J. Psychiatr137, 450, 1980.
Staquet M. J. (Ed.): Cancer therapy: prognostic factors and criteria of response. Raven Press, New York, 1975.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Battelli, T., Mattioli, R., Manocchi, P. et al. ACTH 1–17 effects in oncology. La Ricerca Clin. Lab. 14, 205–209 (1984). https://doi.org/10.1007/BF02904974
Issue Date:
DOI: https://doi.org/10.1007/BF02904974